Age-Period-Cohort Analysis of Secular Trends of Cervical Cancer Incidence and Mortality in China, 1993—2017

doi:10.12114/j.issn.1007-9572.2022.0074

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (13): 1564-1568.DOI: 10.12114/j.issn.1007-9572.2022.0074

Special Issue: 肿瘤最新文章合集

• Original Research·Population Health & Epidemiological Study • Previous Articles Next Articles

Age-Period-Cohort Analysis of Secular Trends of Cervical Cancer Incidence and Mortality in China, 1993—2017

1. Department of Preventive Medicine, Shanxi Datong University, Datong 037009, China
2. The Dean's Office, Shanxi Datong University, Datong 037009, China
3. School of Life Sciences, Shanxi Datong University, Datong 037009, China
4. Party Committee Organization Department, Tongji Medical College of Huazhong University of Science & Technology, Wuhan 430072, China

Received:2022-02-08 Revised:2022-04-06 Published:2022-04-12 Online:2022-04-22
Contact: Zhenkun WANG
About author:
WANG J Y, ZHANG N P, BAI Z Q, et al. Age-period-cohort analysis of secular trends of cervical cancer incidence and mortality in China, 1993—2017[J]. Chinese General Practice, 2022, 25 (13) : 1564-1568.

1993—2017年中国宫颈癌发病率和死亡率长期趋势的年龄-时期-队列模型分析

1．037009　山西省大同市，山西大同大学医学院预防医学系
2．037009　山西省大同市，山西大同大学医学院院长办公室
3．037009　山西省大同市，山西大同大学生命科学学院
4．430030　湖北省武汉市，华中科技大学同济医学院附属同济医院党委办公室

通讯作者: 王震坤
作者简介:
王瑾瑶，张年萍，白志强，等. 1993—2017年中国宫颈癌发病率和死亡率长期趋势的年龄-时期-队列模型分析[J].中国全科医学，2022，25（13）：1564-1568.[www.chinagp.net] 作者贡献：王瑾瑶进行文章的构思与设计、统计学处理、结果的分析与解释、论文撰写与修订、文章的质量控制及审校，并对文章整体负责，监督管理；张年萍进行研究的实施与可行性分析；白志强进行数据收集；王震坤进行数据整理。
基金资助:
国家自然科学基金青年科学基金项目（81903396）——基于时空数据挖掘的国人伤害死亡风险分布特征及影响因素研究

Abstract

Abstract:

Background

Cervical cancer is the seventh most common cancer globally, and the fourth most common cancer in women, accounting for about 12% of all cancers diagnosed among females. Cervical cancer and liver cancer are similar with respect to high prevalent region, with about 85% of the sufferers are from less developed regions.

Objective

To assess the long-term trends of cervical cancer incidence and mortality in China.

Methods

Data about cervical cancer incidence and mortality in Chinese adult females were extracted from the Institute for Health Metrics and Evaluation. Joinpoint regression was used for analyzing the trends of cervical cancer incidence and mortality during 1993—2017. The age-period-cohort model and intrinsic estimator method were adopted for analyzing the effects of age, period, and cohort on cervical cancer incidence and mortality.

Results

Overall, the trends of cervical cancer incidence and mortality totally experienced a significant decrease during 1993—1998, and showed an increasing trend during 2008—2015. Joinpoint regression analysis showed that from 1993 to 2017, the standardized incidence ratio of cervical cancer increased from 9.54/100 000 to 10.88/100 000〔AAPC (95%CI) =0.6 (0.3, 0.9) , P<0.05〕, while its standardized mortality ratio decreased from 4.88/100 000 to 4.48/100 000〔AAPC (95%CI) =-0.3 (-0.5, -0.1) , P<0.05〕. Moreover, cervical cancer incidence increased significantly with age before the age of 59, and the period effect exhibited a general upward trend for both incidence and mortality. The incidence and mortality risks by birth cohort showed a declining trend except for some periods and the risks all peaked in the cohort born in 1916—1920, then leveled off and slightly decreased in younger generations.

Conclusion

Taken together, the decrease in the cohort effect might contribute to the decrease in cervical cancer incidence and mortality rates, while the increase of age and period effects might lead to the increase in its morbidity and mortality rates.

Key words: Uterine cervical neoplasms, Incidence, Mortality, Joinpoint regression, Age-period-cohort model

摘要：

背景

宫颈癌是女性常见的妇科肿瘤之一，占所有女性癌症的12%左右。该病与肝癌一样，约有85%的患者来自欠发达地区。

目的

探讨1993—2017年我国宫颈癌发病率和死亡率的长期趋势。

方法

本研究中所有的发病及死亡数据来源于美国华盛顿大学健康测量与评价中心（IHME）疾病负担网站。本研究首先运用Joinpoint回归分析模型，对中国1993—2017年宫颈癌发病率和死亡率趋势进行分段描述，进一步利用年龄-时期-队列模型和内生因子法估计成年女性宫颈癌发病及死亡风险的年龄效应、时期效应和队列效应。

结果

总的来说，1993—1998年中国宫颈癌发病率和死亡率呈下降趋势，2008—2015年呈上升趋势。Joinpoint回归模型结果显示：1993—2017年，女性宫颈癌的标化发病率从9.54/10万增加到10.88/10万〔AAPC（95%CI）=0.6（0.3，0.9），P<0.05〕，而标化死亡率则从4.88/10万下降到4.48/10万〔AAPC（95%CI）=-0.3（-0.5，-0.1），P<0.05〕。此外，在59岁之前，随着年龄的增长，宫颈癌发病率的年龄效应明显增加，并且发病率和死亡率的周期效应总体呈上升趋势。除某些时期外，出生队列的发病率和死亡率风险呈下降趋势，1916—1920年出生队列的发病率和死亡率风险均达到峰值，然后趋于平稳，在年轻一代中略有下降。

结论

总体而言，队列效应的降低可能导致癌症发病率和死亡率的降低，而年龄效应和周期效应的增加可能导致癌症发病率和死亡率的增加。

关键词: 宫颈肿瘤, 发病率, 死亡率, Joinpoint回归模型, 年龄-时期-队列模型

Jinyao WANG,Nianping ZHANG,Zhiqiang BAI, et al. Age-Period-Cohort Analysis of Secular Trends of Cervical Cancer Incidence and Mortality in China, 1993—2017[J]. Chinese General Practice, 2022, 25(13): 1564-1568. DOI: 10.12114/j.issn.1007-9572.2022.0074.
王瑾瑶,张年萍,白志强等. 1993—2017年中国宫颈癌发病率和死亡率长期趋势的年龄-时期-队列模型分析[J]. 中国全科医学, 2022, 25(13): 1564-1568. DOI: 10.12114/j.issn.1007-9572.2022.0074.

Figures/Tables 7

References 17

[1]	WANG J, BAI Z, WANG Z，et al. Comparison of secular trends in cervical cancer mortality in China and the United States：an age-period-cohort analysis[J]. Int J Environ Res Public Health，2016，13(11):1148. DOI：10.3390/ijerph13111148.
[2]	SU S Y, HUANG J Y, HO C C，et al. Evidence for cervical cancer mortality with screening program in Taiwan，1981—2010：age-period-cohort model[J]. BMC Public Health，2013，13:13. DOI：10.1186/1471-2458-13-13
[3]	International Agency for Research on Cancer. GLOBOCAN 2012：estimated incidence，mortality and prevalence worldwide in 2012[M]. Lyon，France：IARC，2014.
[4]	TORRE L A, BRAY F, SIEGEL R L. Global cancer statistics，2012[J]. CA Cancer J Clin，2015(65):87-108.
[5]	CHEN W, ZHENG R, ZENG H，et al. The updated incidences and mortalities of major cancers in China，2011[J]. Chin J Cancer，2015，34(11):502-507. DOI：10.1186/s40880-015-0042-6.
[6]	LI X, ZHENG R, LI X，et al. Trends of incidence rate and age at diagnosis for cervical cancer in China，from 2000 to 2014[J]. Chin J Cancer Res，2017，29(6):477-486. DOI：10.21147/j.issn.1000-9604.2017.06.02.
[7]	LEVIN C E, SHARMA M, OLSON Z，et al. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China[J]. Vaccine，2015，33(24):2830-2841. DOI：10.1596/978-1-4648-0349-9_ch18.
[8]	HANG D, YIN Y, HAN J，et al. Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population[J]. Virology，2016，488:156-161. DOI：10.1016/j.virol.2015.11.016.
[9]	CANFELL K, SHI J F, LEW J B，et al. Prevention of cervical cancer in rural China：evaluation of HPV vaccination and primary HPV screening strategies[J]. Vaccine，2011，29(13):2487-2494. DOI：10.1016/j.vaccine.2010.12.085.
[10]	李春晖，宇传华. 1990—2009年中国女性乳腺癌死亡趋势的APC模型分析[J]. 中国卫生统计，2015，32(3):393-395.
[11]	FU W J. Ridge Estimator in singular design with application to age-period-cohort analysis of disease rates[J]. Commun Stat Theor M，2000，29:263-278.
[12]	YANG Y, FU W J, LAND K C. A methodological comparison of age-period-cohort models：the intrinsic estimator and conventional generalized linear models[J]. Sociol Methodol，2004，34:75-110.
[13]	AMINISANI N, ARMSTRONG B K, EGGER S，et al. Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia[J]. BMC Cancer，2012，12:491. DOI：10.1186/1471-2407-12-491.
[14]	WANG T, WU M H, WU Y M，et al. A population-based study of invasive cervical cancer patients in Beijing：1993—2008[J]. Chin Med J（Engl），2015，128(24):3298-3304. DOI：10.4103/0366-6999.171420.
[15]	VACCARELLA S, FRANCESCHI S, ENGHOLM G，et al. 50 years of screening in the Nordic countries：quantifying the effects on cervical cancer incidence[J]. Brit J Cancer，2014，111(5):965-969. DOI：10.1038/bjc.2014.362.
[16]	WANG J, LYU H, XUE Z，et al. Temporal trends of common female malignances on breast，cervical，and ovarian cancer mortality in Japan，Republic of Korea，and Singapore：application of the age-period-cohort model[J]. Biomed Res Int，2018，2018:5307459. DOI：10.1155/2018/5307459.
[17]	MOON E K, OH C M, WON Y J，et al. Trends and age-period-cohort effects on the incidence and mortality rate of cervical cancer in Korea[J]. Cancer Res Treat，2017，49(2):526-533. DOI：10.4143/crt.2016.316.

指标	标化率（95%CI）（1/10万）		AAPC（ 95%CI）（%）	APC（95%CI）（%）
指标	1993年	2017年	AAPC（ 95%CI）（%）	阶段1	阶段2	阶段3	阶段4	阶段5
发病率	9.54（8.68，14.65）	10.88（6.86，11.84）	0.6（0.3，0.9）^a	-1.4（-2.0，-0.9）^a	1.3（0.0，2.6）^a	-0.5（-1.1，0.0）	3.3（2.8，3.7）^a	-1.6（-4.0，0.9）
死亡率	4.88（4.50，7.17）	4.48（2.95，4.86）	-0.3（-0.5，-0.1）^a	-3.1（-3.5，-2.7）^a	0.9（0.4，1.3）^a	-2.2（-2.8，-1.6）^a	3.2（2.8，3.7）^a	-2.3（-4.2，-0.4）^a

指标	标化率（95%CI）（1/10万）		AAPC（ 95%CI）（%）	APC（95%CI）（%）
指标	1993年	2017年	AAPC（ 95%CI）（%）	阶段1	阶段2	阶段3	阶段4	阶段5
发病率	9.54（8.68，14.65）	10.88（6.86，11.84）	0.6（0.3，0.9）^a	-1.4（-2.0，-0.9）^a	1.3（0.0，2.6）^a	-0.5（-1.1，0.0）	3.3（2.8，3.7）^a	-1.6（-4.0，0.9）
死亡率	4.88（4.50，7.17）	4.48（2.95，4.86）	-0.3（-0.5，-0.1）^a	-3.1（-3.5，-2.7）^a	0.9（0.4，1.3）^a	-2.2（-2.8，-1.6）^a	3.2（2.8，3.7）^a	-2.3（-4.2，-0.4）^a

项目		发病率		死亡率		项目		发病率		死亡率
项目		效应系数	标准误	效应系数	标准误	项目		效应系数	标准误	效应系数	标准误
年龄（岁）						队列（年）
	20~24	-1.688	0.319	-2.244	0.844		1916—1920	0.442	0.215	0.791	0.311
	25~29	-0.569	0.170	-1.378	0.482		1921—1925	0.367	0.160	0.709	0.255
	30~34	0.017	0.134	-0.760	0.364		1926—1930	0.254	0.138	0.595	0.228
	35~39	0.082	0.129	-0.461	0.314		1931—1935	0.183	0.126	0.494	0.216
	40~44	0.177	0.120	-0.052	0.258		1936—1940	0.116	0.116	0.389	0.211
	45~49	0.316	0.111	0.332	0.214		1941—1945	0.068	0.123	0.291	0.229
	50~54	0.320	0.109	0.507	0.185		1946—1950	0.193	0.125	0.355	0.250
	55~59	0.329	0.105	0.609	0.162		1951—1955	0.182	0.131	0.296	0.278
	60~64	0.285	0.102	0.678	0.146		1956—1960	0.042	0.141	0.082	0.314
	65~69	0.289	0.100	0.837	0.141		1961—1965	0.186	0.140	0.164	0.340
	70~74	0.238	0.102	0.948	0.152		1966—1970	0.157	0.145	0.052	0.374
	75~79	0.205	0.113	0.984	0.182		1971—1975	-0.065	0.161	-0.256	0.432
时期（年）							1976—1980	-0.242	0.188	-0.521	0.532
	1993—1997	-0.127	0.068	-0.109	0.120		1981—1985	-0.294	0.220	-0.699	0.669
	1998—2002	-0.120	0.066	-0.123	0.096		1986—1990	-0.474	0.326	-0.997	1.033
	2003—2007	-0.039	0.064	-0.030	0.089		1991—1995	-1.113	0.952	-1.747	2.922
	2008—2012	0.042	0.064	0.020	0.098		截距	3.433	-	1.036	-
	2013—2017	0.245	0.061	0.241	0.112		AIC值	5.586	-	4.571	-
							BIC值	-119.397	-	-121.794	-

项目		发病率		死亡率		项目		发病率		死亡率
项目		效应系数	标准误	效应系数	标准误	项目		效应系数	标准误	效应系数	标准误
年龄（岁）						队列（年）
	20~24	-1.688	0.319	-2.244	0.844		1916—1920	0.442	0.215	0.791	0.311
	25~29	-0.569	0.170	-1.378	0.482		1921—1925	0.367	0.160	0.709	0.255
	30~34	0.017	0.134	-0.760	0.364		1926—1930	0.254	0.138	0.595	0.228
	35~39	0.082	0.129	-0.461	0.314		1931—1935	0.183	0.126	0.494	0.216
	40~44	0.177	0.120	-0.052	0.258		1936—1940	0.116	0.116	0.389	0.211
	45~49	0.316	0.111	0.332	0.214		1941—1945	0.068	0.123	0.291	0.229
	50~54	0.320	0.109	0.507	0.185		1946—1950	0.193	0.125	0.355	0.250
	55~59	0.329	0.105	0.609	0.162		1951—1955	0.182	0.131	0.296	0.278
	60~64	0.285	0.102	0.678	0.146		1956—1960	0.042	0.141	0.082	0.314
	65~69	0.289	0.100	0.837	0.141		1961—1965	0.186	0.140	0.164	0.340
	70~74	0.238	0.102	0.948	0.152		1966—1970	0.157	0.145	0.052	0.374
	75~79	0.205	0.113	0.984	0.182		1971—1975	-0.065	0.161	-0.256	0.432
时期（年）							1976—1980	-0.242	0.188	-0.521	0.532
	1993—1997	-0.127	0.068	-0.109	0.120		1981—1985	-0.294	0.220	-0.699	0.669
	1998—2002	-0.120	0.066	-0.123	0.096		1986—1990	-0.474	0.326	-0.997	1.033
	2003—2007	-0.039	0.064	-0.030	0.089		1991—1995	-1.113	0.952	-1.747	2.922
	2008—2012	0.042	0.064	0.020	0.098		截距	3.433	-	1.036	-
	2013—2017	0.245	0.061	0.241	0.112		AIC值	5.586	-	4.571	-
							BIC值	-119.397	-	-121.794	-

Age-Period-Cohort Analysis of Secular Trends of Cervical Cancer Incidence and Mortality in China, 1993—2017

1993—2017年中国宫颈癌发病率和死亡率长期趋势的年龄-时期-队列模型分析

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 17

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Wenpeng, HAN Mengqi, WANG Yuxin, WANG Guoping. Trends and Projections of Incidence and Mortality of Nasopharyngeal Carcinoma in China from 1990 to 2019 [J]. Chinese General Practice, 2023, 26(34): 4269-4276.
[2]	MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou. Interpretation of Report on Cardiovascular Health and Diseases in China 2022 [J]. Chinese General Practice, 2023, 26(32): 3975-3994.
[3]	JIA Yu, ZHOU Zitong, CAO Xuehua, HU Wanqin, XIANG Feng, XIONG Langyu, WANG Xiaoxia. Incidence of Perimenopausal Syndrome in Chinese Women Aged 40 to 65 Years: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4080-4088.
[4]	MA Yanyan, REN Fuxian, WANG Yu, GAO Dengfeng. The Prediction Value of (Neutrophil+Monocyte) /Lymphocyte Ratio on In-hospital Mortality of Heart Failure Patients [J]. Chinese General Practice, 2023, 26(30): 3791-3796.
[5]	XU Zhe, ZHANG Jinxia, ZHANG Xiuhong, XIE Kaihong. Relationship between Sleep Duration and All-cause Mortality in Middle-aged and Older Adults [J]. Chinese General Practice, 2023, 26(28): 3507-3512.
[6]	SUN Xuhai, SHI Xiuxiu, ZHAO Zhengzheng, HAN Jinxiang. Characteristics of Newly Increased and Deceased Patients with Severe Mental Illness in a Community in Beijing from 2011 to 2021 [J]. Chinese General Practice, 2023, 26(19): 2402-2407.
[7]	LIU Lu, JIANG Yunlan, PENG Hanmei, LU Yutong, LIU Mingting, LIAO Shiqin. Dysphagia Incidence after Cardiac Surgery: a Meta-analysis [J]. Chinese General Practice, 2023, 26(18): 2293-2300.
[8]	SU Afang, ZHU Guoling, ZHANG Yunshui, CHEN Shuohua, ZHAO Xiujuan, YANG Wenhao, WANG Yinjie, WANG Fengfei, XIN Yingying, WU Shouling, ZHANG Jie, JIANG Xiaozhong. Association between Baseline Fasting Plasma Glucose Levels and Risk of Acute Pancreatitis in Non-obese Population: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(18): 2203-2208.
[9]	LIANG Shanshan, ZHOU Zhihua, LI Chengcheng, CHEN Huijing, ZHOU Shangcheng. Diabetes in China: Burden Analysis between 1990 and 2019 and Incidence Prediction between 2020 and 2030 [J]. Chinese General Practice, 2023, 26(16): 2013-2019.
[10]	HUANG Pengfei, ZHANG Yunjing, MA Dong, WU Yunyan, ZHAO Yongbo. Relationship between Admission Serum Chloride Level and Postoperative 30-day Mortality in Patients with Acute Stanford Type A Aortic Dissection [J]. Chinese General Practice, 2023, 26(11): 1330-1339.
[11]	DUAN Zhaohui, ZHANG Min, XU Jieru, XIONG Wenjing, CHEN Lei, ZHAO Xiangling, ZHANG Yiyun, RANG Weiqing. Past (2000-2019) and Future (2020-2024) Trends of Brain Cancer Mortality in China [J]. Chinese General Practice, 2023, 26(06): 734-741.
[12]	ZHANG Weizong, YUAN Hong, SUN Jindong, YU Huamin, SHI Mingjuan, HU Haiqiang, HE Haiying, YE Li, ZHANG Huihui, BAI Xinghua, SHEN Chaofeng, TU Sijia, WANG Yang, WANG Gang, ZHAO Xiaofeng, YU Tao, LI Cairong, ZHANG Zhi, ZHOU Donglai, CAI Mengyang, NING Le. Risk Factors of In-hospital Death in COVID-19 Patients: a Meta-analysis [J]. Chinese General Practice, 2023, 26(05): 607-620.
[13]	WANG Hongxin, FAN Wenlong, YANG Xiaoyu, CHEN Dongyu, HUANG Qiao, PAN Suyue, WANG Pu, HU Min, HE Yuqing. Protein-energy Malnutrition Incidence in China: Trend in 1990-2019 and Future Trend in 2020-2029 [J]. Chinese General Practice, 2023, 26(05): 591-597.
[14]	ZHAO Mingyang, ZHOU Qianyu, WANG Rongrong, WANG Zongxi, HE Wenqian, ZHANG Wensen, ZHANG Hengzhen, TIAN Zhuoyang, WU Ke, WANG Biyao, SUN Changqing. Influencing Factors of the Incidence of Pulmonary Tuberculosis in China: an Analysis Using the Geographically and Temporally Weighted Regression Model [J]. Chinese General Practice, 2023, 26(05): 583-590.
[15]	ZHAO Honglin, LI Qiaomei, LI Tingting, DING Guowu. AIDS in China from 2004 to 2018: Incidence and Mortality Trends and Age-period-cohort Effect Analysis [J]. Chinese General Practice, 2023, 26(04): 409-416.